Overview

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Status:
RECRUITING

Trial end date:
2026-01-07

Target enrollment:

Participant gender:

Summary

This study will measure the effects of multiple doses of AZD6234 and a combination of AZD6234 and AZD9550 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Acetaminophen
Ethinyl Estradiol
Levonorgestrel